Page Title
Drug Development Pipeline
CMTX-101
Status
Phase TwoTherapeutic Approach
Anti-Infective
CMTX-101 is an anti-infective therapy that aims to disrupt bacterial biofilms, one of the primary causes of antibiotic resistance. Biofilms are protective structures that shield bacteria from both the immune system and antibiotics.
CMTX-101 specifically targets biofilms, potentially leaving bacteria more susceptible to antibiotics and the body’s own immune response. This approach could also help reduce the inflammation that results from chronic infections in CF. In lab tests, CMTX-101 was able to disrupt biofilms across many species of bacteria, including key CF pathogens such as Pseudomonas aeruginosa, Burkholderia cepacia, and nontuberculous mycobacteria.
Status
A Phase 1b/2a study is underway to test the safety of CMTX-101 (in combination with inhaled Tobramycin) in people with CF with Pseudomonas infections.
Sponsor
This program is sponsored by Clarametyx Biosciences and partially funded by the Cystic Fibrosis Foundation. The trial is being conducted within the Therapeutics Development Network.

CONTACT THE CLINICAL TRIAL NAVIGATOR
Get personalized assistance and answers to your clinical trial questions.
Learn MoreSign up for clinical trial alerts
Get email updates about clinical trials that matter to you.
Explore clinical trials
Be a part of the movement transforming the future of cystic fibrosis treatment.
Learn More